Cargando…

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir

BACKGROUND: Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat patients with hepatitis C virus infection. It is currently unknown whether adding ribavirin (RBV) to SOF + SIM, which raises the pill count from two up to eight pills a day, impacts adherence. The aim of this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walker, David R, Juday, Timothy R, Manthena, Shivaji R, Jing, Yonghua, Sood, Vipan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687623/ https://www.ncbi.nlm.nih.gov/pubmed/26719716 http://dx.doi.org/10.2147/CEOR.S87261

Ejemplares similares

Sofosbuvir in combination with ribavirin or simeprevir: real-life study of patients with hepatitis C genotype 4
por: Abdel-Moneim, Adel, et al.
Publicado: (2019)

Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium
por: Degré, Delphine, et al.
Publicado: (2017)

Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease
por: Maruyama, Anna, et al.
Publicado: (2016)

Treatment of Recurrent Hepatitis C Genotype-4 Post-Liver Transplantation with Sofosbuvir plus Simeprevir
por: Ascha, Mustafa, et al.
Publicado: (2015)

Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results
por: Bichoupan, Kian, et al.
Publicado: (2017)

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C
por: Sarkar, Souvik, et al.
Publicado: (2015)

Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation
por: Issa, D., et al.
Publicado: (2016)

Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Infection After Liver Transplantation
por: Khemichian, Saro, et al.
Publicado: (2015)

Successful treatment of hepatitis C genotype 4 using sofosbuvir, daclatasvir, simeprevir and ribavirin in Egyptian patients with direct-acting antiviral agent treatment failure
por: Mohamed, Hala, et al.
Publicado: (2022)

Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis
por: Wei, Bin, et al.
Publicado: (2018)

Benefit–risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir
por: Gaetano, John N
Publicado: (2014)

Photo-induced drug eruption in a patient on combination simeprevir/sofosbuvir for hepatitis C
por: Eyre, Zachary W., et al.
Publicado: (2016)

Daclatasvir plus Sofosbuvir with or without ribavirin in patients with chronic Hepatitis C genotype 3a in Pakistani population - A real world experience
por: Butt, Zamir, et al.
Publicado: (2019)

Miliary tuberculosis infection during hepatitis C treatment with sofosbuvir and ledipasvir plus ribavirin
por: Ballester-Ferré, Maria Pilar, et al.
Publicado: (2017)

Safety and Efficacy of Sofosbuvir with Ribavirin® in Hepatitis C, Genotype 3 Patients with Cirrhosis: A Real-world Experience
por: Butt, Nazish, et al.
Publicado: (2019)

Effect of Sofosbuvir plus Ribavirin therapy on hepatitis C patients in Pakistan: a retrospective study
por: Jamil, Zubia, et al.
Publicado: (2018)

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)
por: Lawitz, Eric, et al.
Publicado: (2016)

Ledipasvir/sofosbuvir and ribavirin for the treatment of ribavirin-refractory persistent hepatitis E virus infection
por: Gallacher, Jennifer, et al.
Publicado: (2023)

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
por: Welzel, Tania M, et al.
Publicado: (2017)

Effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis C virus genotype 4 patients
por: Abdel-Moneim, Adel, et al.
Publicado: (2018)

Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis
por: Flamm, Steven, et al.
Publicado: (2023)

Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection
por: Wang, Gary P., et al.
Publicado: (2018)

Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan
por: Igarashi, Ataru, et al.
Publicado: (2019)

Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
por: Liu, Chen-Hua, et al.
Publicado: (2018)

Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
por: Tang, L., et al.
Publicado: (2018)

Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis
por: He, Qiu-Feng, et al.
Publicado: (2016)

Successful Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin Retreatment for a Chronic Hepatitis C Genotype 2a Patient Who Relapsed after Sofosbuvir Plus Ribavirin Treatment
por: Ishikawa, Toru, et al.
Publicado: (2018)

Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report
por: Ende, Alexander R., et al.
Publicado: (2015)

Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis
por: Nguyen, Nghia H, et al.
Publicado: (2016)

Sofosbuvir and ribavirin in acute hepatitis C–infected patient with decompensated cirrhosis
por: Liu, Hui, et al.
Publicado: (2016)

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)
por: Asselah, Tarik, et al.
Publicado: (2016)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
por: McEwan, Phil, et al.
Publicado: (2017)

Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme
por: Hézode, Christophe, et al.
Publicado: (2017)

Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis
por: Seo, Hee Yeon, et al.
Publicado: (2020)

Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
por: Liu, Chen-Hua, et al.
Publicado: (2021)

Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials
por: Yee, Brittany E, et al.
Publicado: (2016)

Application of different spectrophotometric methods for quantitative analysis of direct acting antiviral drugs simeprevir and sofosbuvir
por: Ramzy, Sherif, et al.
Publicado: (2022)

Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin
por: Nakayama, Masahiko, et al.
Publicado: (2015)

Simeprevir with peginterferon/ribavirin for patients with hepatitis C virus genotype 1: high frequency of viral relapse in elderly patients
por: Watanabe, Takao, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2hbgs1ehnq6bq7gmpkrmbdd4dj